Document Detail


Pharmacotherapy for smoking cessation: current advances and research topics.
MedLine Citation:
PMID:  21476609     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Promoting smoking cessation is among the key medical interventions aimed at reducing worldwide morbidity and mortality in this century. Both behavioural counselling and pharmacotherapy have been shown to significantly increase long-term abstinence rates, and combining the two treatment modalities is recommended. This article provides an update on pharmacotherapy for smoking cessation in the general population. Current first-line agents used to support quit attempts are nicotine replacement therapy (NRT), bupropion and varenicline. Research suggests that abstinence rates can be increased by combining different forms of NRT or simultaneously administering NRT and non-nicotine medications. New treatments targeting the nicotinic acetylcholine receptor as well as other pathophysiological pathways involved in nicotine addiction are being developed, with nicotine vaccines now being tested in phase III clinical trials. Among the numerous research topics currently addressed, pharmacogenetics and tailoring therapy to specific groups of smokers look most promising. However, substantial progress is unlikely to be made unless social gradients impeding effective treatment of all smokers are overcome. In addition, public smoking bans and reimbursement of medication costs are crucial in reducing the future burden of disease caused by smoking on a global level.
Authors:
Tobias Raupach; Constant P van Schayck
Related Documents :
21500669 - Violence against women in north carolina.
11457609 - Forensic entomology: application, education and research in western australia.
21443739 - Marine sponges and their microbial symbionts: love and other relationships.
20832209 - Uniqueness in the forensic identification sciences-fact or fiction?
21471909 - Overcoming the hurdles: setting up clinical trials in three uk hospices.
21136749 - In vivo secretome sampling technology for proteomics.
11710849 - Inquiry cantos: poetics of developmental disability.
15705199 - Cytojournal's move to fund open access.
16277569 - Commentary on the pleasures of solving impossible problems of experimental physiology.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  CNS drugs     Volume:  25     ISSN:  1172-7047     ISO Abbreviation:  CNS Drugs     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-04-11     Completed Date:  2011-07-27     Revised Date:  2011-12-06    
Medline Journal Info:
Nlm Unique ID:  9431220     Medline TA:  CNS Drugs     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  371-82     Citation Subset:  IM    
Affiliation:
Department of Cardiology and Pneumology, University Hospital Gttingen, Gttingen, Germany. raupach@med.uni-goettingen.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Topical
Bupropion / economics,  therapeutic use*
Dopamine Uptake Inhibitors / economics,  therapeutic use*
Female
Humans
Male
Nicotine / administration & dosage,  economics,  therapeutic use*
Nicotinic Agonists / administration & dosage,  economics,  therapeutic use*
Randomized Controlled Trials as Topic
Smoking / mortality,  prevention & control*
Smoking Cessation* / economics,  methods
Tobacco Use Disorder / drug therapy*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Dopamine Uptake Inhibitors; 0/Nicotinic Agonists; 34841-39-9/Bupropion; 54-11-5/Nicotine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tapentadol in pain management: a ?-opioid receptor agonist and noradrenaline reuptake inhibitor.
Next Document:  Antipsychotic polypharmacy in schizophrenia: benefits and risks.